<?xml version='1.0' encoding='utf-8'?>
<document id="26505529"><sentence text="Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects."><entity charOffset="50-70" id="DDI-PubMed.26505529.s1.e0" text="Ursodeoxycholic Acid" /><entity charOffset="74-86" id="DDI-PubMed.26505529.s1.e1" text="Glycyrrhizin" /><entity charOffset="91-101" id="DDI-PubMed.26505529.s1.e2" text="Ombitasvir" /><entity charOffset="102-114" id="DDI-PubMed.26505529.s1.e3" text="Paritaprevir" /><entity charOffset="115-124" id="DDI-PubMed.26505529.s1.e4" text="Ritonavir" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e0" e2="DDI-PubMed.26505529.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e0" e2="DDI-PubMed.26505529.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e0" e2="DDI-PubMed.26505529.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e0" e2="DDI-PubMed.26505529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e0" e2="DDI-PubMed.26505529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e1" e2="DDI-PubMed.26505529.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e1" e2="DDI-PubMed.26505529.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e1" e2="DDI-PubMed.26505529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e1" e2="DDI-PubMed.26505529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e2" e2="DDI-PubMed.26505529.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e2" e2="DDI-PubMed.26505529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e2" e2="DDI-PubMed.26505529.s1.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e3" e2="DDI-PubMed.26505529.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s1.e3" e2="DDI-PubMed.26505529.s1.e4" /></sentence><sentence text="The 2 direct-acting antiviral combination (2D) of ombitasvir and paritaprevir (coadministered with ritonavir) is being evaluated for the treatment of chronic hepatitis C virus infection in Japan"><entity charOffset="50-60" id="DDI-PubMed.26505529.s2.e0" text="ombitasvir" /><entity charOffset="65-77" id="DDI-PubMed.26505529.s2.e1" text="paritaprevir" /><entity charOffset="99-108" id="DDI-PubMed.26505529.s2.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26505529.s2.e0" e2="DDI-PubMed.26505529.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s2.e0" e2="DDI-PubMed.26505529.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s2.e0" e2="DDI-PubMed.26505529.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s2.e1" e2="DDI-PubMed.26505529.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s2.e1" e2="DDI-PubMed.26505529.s2.e2" /></sentence><sentence text=" Ursodeoxycholic acid (UDCA) and glycyrrhizin (GCR) are hepatoprotective agents widely used in Japan"><entity charOffset="1-21" id="DDI-PubMed.26505529.s3.e0" text="Ursodeoxycholic acid" /><entity charOffset="23-27" id="DDI-PubMed.26505529.s3.e1" text="UDCA" /><entity charOffset="33-45" id="DDI-PubMed.26505529.s3.e2" text="glycyrrhizin" /><entity charOffset="47-50" id="DDI-PubMed.26505529.s3.e3" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e0" e2="DDI-PubMed.26505529.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e0" e2="DDI-PubMed.26505529.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e0" e2="DDI-PubMed.26505529.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e0" e2="DDI-PubMed.26505529.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e1" e2="DDI-PubMed.26505529.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e1" e2="DDI-PubMed.26505529.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e1" e2="DDI-PubMed.26505529.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e2" e2="DDI-PubMed.26505529.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s3.e2" e2="DDI-PubMed.26505529.s3.e3" /></sentence><sentence text=" A drug-drug interaction (DDI) study was conducted to guide dosing recommendations for UDCA and GCR when coadministered with the 2D regimen"><entity charOffset="87-89" id="DDI-PubMed.26505529.s4.e0" text="UDCA" /><entity charOffset="96-98" id="DDI-PubMed.26505529.s4.e1" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s4.e0" e2="DDI-PubMed.26505529.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s4.e0" e2="DDI-PubMed.26505529.s4.e1" /></sentence><sentence text="" /><sentence text="DDIs between the 2D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg orally once daily) and UDCA (50 mg orally 3 times daily) or GCR (80 mg intravenously once daily) were evaluated in a 2-arm, multiple-dose study in 24 Japanese healthy subjects under fed conditions"><entity charOffset="29-39" id="DDI-PubMed.26505529.s6.e0" text="ombitasvir" /><entity charOffset="40-52" id="DDI-PubMed.26505529.s6.e1" text="paritaprevir" /><entity charOffset="53-62" id="DDI-PubMed.26505529.s6.e2" text="ritonavir" /><entity charOffset="100-108" id="DDI-PubMed.26505529.s6.e3" text="UDCA" /><entity charOffset="137-145" id="DDI-PubMed.26505529.s6.e4" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e0" e2="DDI-PubMed.26505529.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e0" e2="DDI-PubMed.26505529.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e0" e2="DDI-PubMed.26505529.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e0" e2="DDI-PubMed.26505529.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e0" e2="DDI-PubMed.26505529.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e1" e2="DDI-PubMed.26505529.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e1" e2="DDI-PubMed.26505529.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e1" e2="DDI-PubMed.26505529.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e1" e2="DDI-PubMed.26505529.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e2" e2="DDI-PubMed.26505529.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e2" e2="DDI-PubMed.26505529.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e2" e2="DDI-PubMed.26505529.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e3" e2="DDI-PubMed.26505529.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s6.e3" e2="DDI-PubMed.26505529.s6.e4" /></sentence><sentence text=" Pharmacokinetic and safety evaluations were performed when UDCA or GCR and the 2D regimen were administered alone and during coadministration"><entity charOffset="60-62" id="DDI-PubMed.26505529.s7.e0" text="UDCA" /><entity charOffset="68-70" id="DDI-PubMed.26505529.s7.e1" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s7.e0" e2="DDI-PubMed.26505529.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s7.e0" e2="DDI-PubMed.26505529.s7.e1" /></sentence><sentence text=" Exposures from coadministration of the 2D regimen plus UDCA or GCR versus the 2D regimen, UDCA, or GCR alone were compared using repeated-measures analyses of natural logarithms of the maximum plasma concentration (Cmax) and area under the curve (AUC)"><entity charOffset="56-58" id="DDI-PubMed.26505529.s8.e0" text="UDCA" /><entity charOffset="91-93" id="DDI-PubMed.26505529.s8.e1" text="UDCA" /><entity charOffset="64-66" id="DDI-PubMed.26505529.s8.e2" text="GCR" /><entity charOffset="100-102" id="DDI-PubMed.26505529.s8.e3" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e0" e2="DDI-PubMed.26505529.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e0" e2="DDI-PubMed.26505529.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e0" e2="DDI-PubMed.26505529.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e0" e2="DDI-PubMed.26505529.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e2" e2="DDI-PubMed.26505529.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e2" e2="DDI-PubMed.26505529.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e2" e2="DDI-PubMed.26505529.s8.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e1" e2="DDI-PubMed.26505529.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s8.e1" e2="DDI-PubMed.26505529.s8.e3" /></sentence><sentence text="" /><sentence text="After coadministration of the 2D regimen and UDCA, steady-state exposures (Cmax and AUC) of ombitasvir, paritaprevir, and ritonavir showed a ≤9% change, and UDCA exposures showed a ≤20% change compared with administration alone"><entity charOffset="92-102" id="DDI-PubMed.26505529.s10.e0" text="ombitasvir" /><entity charOffset="104-116" id="DDI-PubMed.26505529.s10.e1" text="paritaprevir" /><entity charOffset="122-131" id="DDI-PubMed.26505529.s10.e2" text="ritonavir" /><entity charOffset="45-53" id="DDI-PubMed.26505529.s10.e3" text="UDCA" /><entity charOffset="157-165" id="DDI-PubMed.26505529.s10.e4" text="UDCA" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e3" e2="DDI-PubMed.26505529.s10.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e3" e2="DDI-PubMed.26505529.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e3" e2="DDI-PubMed.26505529.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e3" e2="DDI-PubMed.26505529.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e3" e2="DDI-PubMed.26505529.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e0" e2="DDI-PubMed.26505529.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e0" e2="DDI-PubMed.26505529.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e0" e2="DDI-PubMed.26505529.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e0" e2="DDI-PubMed.26505529.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e1" e2="DDI-PubMed.26505529.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e1" e2="DDI-PubMed.26505529.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e1" e2="DDI-PubMed.26505529.s10.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e2" e2="DDI-PubMed.26505529.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s10.e2" e2="DDI-PubMed.26505529.s10.e4" /></sentence><sentence text=" When the 2D regimen and GCR were coadministered, steady-state exposures of ombitasvir, paritaprevir, and ritonavir were not affected (≤9% change), GCR AUC increased by 49%, and GCR Cmax was unaffected (&lt;1% change)"><entity charOffset="76-86" id="DDI-PubMed.26505529.s11.e0" text="ombitasvir" /><entity charOffset="88-100" id="DDI-PubMed.26505529.s11.e1" text="paritaprevir" /><entity charOffset="106-115" id="DDI-PubMed.26505529.s11.e2" text="ritonavir" /><entity charOffset="25-33" id="DDI-PubMed.26505529.s11.e3" text="GCR" /><entity charOffset="148-156" id="DDI-PubMed.26505529.s11.e4" text="GCR" /><entity charOffset="178-186" id="DDI-PubMed.26505529.s11.e5" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e3" e2="DDI-PubMed.26505529.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e3" e2="DDI-PubMed.26505529.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e3" e2="DDI-PubMed.26505529.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e3" e2="DDI-PubMed.26505529.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e3" e2="DDI-PubMed.26505529.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e3" e2="DDI-PubMed.26505529.s11.e5" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e0" e2="DDI-PubMed.26505529.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e0" e2="DDI-PubMed.26505529.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e0" e2="DDI-PubMed.26505529.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e0" e2="DDI-PubMed.26505529.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e0" e2="DDI-PubMed.26505529.s11.e5" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e1" e2="DDI-PubMed.26505529.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e1" e2="DDI-PubMed.26505529.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e1" e2="DDI-PubMed.26505529.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e1" e2="DDI-PubMed.26505529.s11.e5" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e2" e2="DDI-PubMed.26505529.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e2" e2="DDI-PubMed.26505529.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e2" e2="DDI-PubMed.26505529.s11.e5" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e4" e2="DDI-PubMed.26505529.s11.e4" /><pair ddi="false" e1="DDI-PubMed.26505529.s11.e4" e2="DDI-PubMed.26505529.s11.e5" /></sentence><sentence text="" /><sentence text="No dose adjustment is needed for UDCA, GCR, or the 2D regimen when UDCA or GCR is coadministered with the 2D regimen in hepatitis C virus-infected patients under fed conditions"><entity charOffset="33-35" id="DDI-PubMed.26505529.s13.e0" text="UDCA" /><entity charOffset="67-69" id="DDI-PubMed.26505529.s13.e1" text="UDCA" /><entity charOffset="39-41" id="DDI-PubMed.26505529.s13.e2" text="GCR" /><entity charOffset="75-77" id="DDI-PubMed.26505529.s13.e3" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e0" e2="DDI-PubMed.26505529.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e0" e2="DDI-PubMed.26505529.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e0" e2="DDI-PubMed.26505529.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e0" e2="DDI-PubMed.26505529.s13.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e2" e2="DDI-PubMed.26505529.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e2" e2="DDI-PubMed.26505529.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e2" e2="DDI-PubMed.26505529.s13.e3" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e1" e2="DDI-PubMed.26505529.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26505529.s13.e1" e2="DDI-PubMed.26505529.s13.e3" /></sentence><sentence text=" Clinical monitoring of patients using GCR is recommended due to an approximately 50% increase in GCR AUC when coadministered with the 2D regimen"><entity charOffset="39-41" id="DDI-PubMed.26505529.s14.e0" text="GCR" /><entity charOffset="98-100" id="DDI-PubMed.26505529.s14.e1" text="GCR" /><pair ddi="false" e1="DDI-PubMed.26505529.s14.e0" e2="DDI-PubMed.26505529.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26505529.s14.e0" e2="DDI-PubMed.26505529.s14.e1" /></sentence><sentence text="" /></document>